Department of Pathology, School of Medicine, The Johns Hopkins University, Baltimore, Maryland.
J Histochem Cytochem. 2019 Sep;67(9):633-641. doi: 10.1369/0022155419861092. Epub 2019 Jun 26.
Progression of renal parenchyma injury is characterized by increasing interstitial fibrosis and tubular atrophy, irrespective of the cause. Histopathologic assessment of renal tissue obtained by biopsy remains the gold standard for determining the presence and extent of tubulointerstitial scarring. Discovery of robust non-invasive means for capturing a snapshot and for longitudinal monitoring of parenchymal deterioration has been the focus of intense multimodal effort by investigators within the renal community and beyond. Research in this field has included the use of in vitro and in vivo experimental models and has fostered the development and evaluation of tissue and biofluid assays for novel analytes with potential translation to the diagnosis and prognosis of kidney disease. Here, we examine recent advances in the search of "biomarkers" for detection of renal tubulointerstitial scarring and prediction of renal outcome in human renal disease.
肾实质损伤的进展以间质纤维化和肾小管萎缩的增加为特征，与病因无关。通过活检获得的肾组织的组织病理学评估仍然是确定肾小管间质瘢痕存在和程度的金标准。发现可靠的非侵入性方法来捕捉实质恶化的快照和进行纵向监测一直是肾脏领域内外研究人员的多模式努力的重点。该领域的研究包括使用体外和体内实验模型，并促进了新型分析物的组织和生物流体分析的开发和评估，这些分析物具有将其转化为肾脏病诊断和预后的潜力。在这里，我们研究了在寻找“生物标志物”以检测人类肾脏疾病中的肾小管间质瘢痕和预测肾脏结局方面的最新进展。
